The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Advances in cobalt complexes as anticancer agents
Abstract
This perspective describes the advances in cobalt-containing compounds as anticancer agents. Cobalt, being an essential trace element, offers a less toxic alternative to traditional platinum-based anticancer drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-like Drugs
VANE, J. R. (1971) · Nature New Biology · doi:10.1038/newbio231232a0 · Cited by 8,605
The resurgence of platinum-based cancer chemotherapy
Kelland, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2167 · Cited by 4,717
Schafer, F. Q., & Buettner, G. R. (2001) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(01)00480-4 · Cited by 4,587
Platinum Compounds: a New Class of Potent Antitumour Agents
ROSENBERG, B., VANCAMP, L., TROSKO, J. E., & MANSOUR, V. H. (1969) · Nature · doi:10.1038/222385a0 · Cited by 3,972
Cellular processing of platinum anticancer drugs
Wang, D., & Lippard, S. J. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1691 · Cited by 3,801
Ullmann's Encyclopedia of Industrial Chemistry
(2000) · Wiley eBooks · doi:10.1002/14356007 · Cited by 3,543
Cisplatin: mode of cytotoxic action and molecular basis of resistance
Siddik, Z. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206933 · Cited by 3,335
Targeting hypoxia in cancer therapy
Wilson, W. R., & Hay, M. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3064 · Cited by 3,172
Exploiting tumour hypoxia in cancer treatment
Brown, J. M., & Wilson, W. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1367 · Cited by 2,828
Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations
Coussens, L. M., Fingleton, B., & Matrisian, L. M. (2002) · Science · doi:10.1126/science.1067100 · Cited by 2,761
Goldberg, R. M., Sargent, D. J., Morton, R. F., Fuchs, C. S., Ramanathan, R. K., Williamson, S. K., Findlay, B. P., Pitot, H. C., & Alberts, S. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.046 · Cited by 2,249
Gray, L. H., Conger, A. D., Ebert, M., Hornsey, S., & Scott, O. C. A. (1953) · The British Journal of Radiology · doi:10.1259/0007-1285-26-312-638 · Cited by 2,158
Current Status of Platinum-Based Antitumor Drugs
Wong, E., & Giandomenico, C. M. (1999) · Chemical Reviews · doi:10.1021/cr980420v · Cited by 1,800
Giacchetti, S., Perpoint, B., Zidani, R., Le Bail, N., Faggiuolo, R., Focan, C., Chollet, P., Llory, J. F., Letourneau, Y., Coudert, B., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.136 · Cited by 1,403
Direct Cellular Responses to Platinum-Induced DNA Damage
Jung, Y., & Lippard, S. J. (2007) · Chemical Reviews · doi:10.1021/cr068207j · Cited by 1,391
Matrix metalloproteinases: a tail of a frog that became a prince
Brinckerhoff, C. E., & Matrisian, L. M. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm763 · Cited by 1,105
On the medicinal chemistry of gold complexes as anticancer drugs
Ott, I. (2009) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2009.02.019 · Cited by 825
Rothenberg, M. L., Oza, A. M., Bigelow, R. H., Berlin, J. D., Marshall, J. L., Ramanathan, R. K., Hart, L. L., Gupta, S., Garay, C. A., Burger, B. G., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.126 · Cited by 646
Non Platinum Metal Complexes as Anti‐cancer Drugs
Ott, I., & Gust, R. (2007) · Archiv der Pharmazie · doi:10.1002/ardp.200600151 · Cited by 609
Platinum neurotoxicity pharmacogenetics
McWhinney, S. R., Goldberg, R. M., & McLeod, H. L. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0840 · Cited by 574
Inhibition of transcription by platinum antitumor compounds
Todd, R. C., & Lippard, S. J. (2009) · Metallomics · doi:10.1039/b907567d · Cited by 539
Glossary of terms used in medicinal chemistry (IUPAC Recommendations 1998)
Wermuth, C. G., Ganellin, C. R., Lindberg, P., & Mitscher, L. A. (1998) · Pure and Applied Chemistry · doi:10.1351/pac199870051129 · Cited by 529
Redox activation of metal-based prodrugs as a strategy for drug delivery
Graf, N., & Lippard, S. J. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.01.007 · Cited by 523
Approaching tumour therapy beyond platinum drugs
Bergamo, A., Gaiddon, C., Schellens, J. H. M., Beijnen, J. H., & Sava, G. (2012) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2011.09.030 · Cited by 514
Matrix metalloproteinases in tumor invasion: Role for cell migration
Nabeshima, K., Inoue, T., Shimao, Y., & Sameshima, T. (2002) · Pathology International · doi:10.1046/j.1440-1827.2002.01343.x · Cited by 446
Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs
Bergamo, A., & Sava, G. (2011) · Dalton Transactions · doi:10.1039/c0dt01816c · Cited by 440
Modifications of DNA by platinum complexes
Brabec, V., & Kasparkova, J. (2005) · Drug Resistance Updates · doi:10.1016/j.drup.2005.04.006 · Cited by 373
Raja, D. S., Bhuvanesh, N. S. P., & Natarajan, K. (2012) · Dalton Transactions · doi:10.1039/c2dt12274j · Cited by 364
Cosse, J.-P., & Michiels, C. (2008) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152008785914798 · Cited by 348
The initial clinical trial of nitrogen mustard
Gilman, A. (1963) · The American Journal of Surgery · doi:10.1016/0002-9610(63)90232-0 · Cited by 338
Biological Activity of Complex Ions
DWYER, F. P., GYARFAS, E. C., ROGERS, W. P., & KOCH, J. H. (1952) · Nature · doi:10.1038/170190a0 · Cited by 289
Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial
Bramhall, S. R., Hallissey, M. T., Whiting, J., Scholefield, J., Tierney, G., Stuart, R. C., Hawkins, R. E., McCulloch, P., Maughan, T., Brown, P. D., et al. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600310 · Cited by 265
Design of anticancer prodrugs for reductive activation
Chen, Y., & Hu, L. (2009) · Medicinal Research Reviews · doi:10.1002/med.20137 · Cited by 238
Ott, I., Schmidt, K., Kircher, B., Schumacher, P., Wiglenda, T., & Gust, R. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049326z · Cited by 207
Cobalt derivatives as promising therapeutic agents
Heffern, M. C., Yamamoto, N., Holbrook, R. J., Eckermann, A. L., & Meade, T. J. (2013) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2012.11.019 · Cited by 204
Gallium-Containing Anticancer Compounds
Chitambar, C. R. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.69 · Cited by 198
Carboplatin: the clinical spectrum to date
Canetta, R., Rozencweig, M., & Carter, S. K. (1985) · Cancer Treatment Reviews · doi:10.1016/0305-7372(85)90027-1 · Cited by 197
Ware, D. C., Palmer, B. D., Wilson, W. R., & Denny, W. A. (1993) · Journal of Medicinal Chemistry · doi:10.1021/jm00065a006 · Cited by 193
Bioreductive activation and drug chaperoning in cobalt pharmaceuticals
Hall, M. D., Failes, T. W., Yamamoto, N., & Hambley, T. W. (2007) · Dalton Transactions · doi:10.1039/b707121c · Cited by 188
Cobalt: Its Role in Health and Disease
Yamada, K. (2013) · Metal Ions in Life Sciences · doi:10.1007/978-94-007-7500-8_9 · Cited by 176
Delivery and release of curcumin by a hypoxia-activated cobalt chaperone: a XANES and FLIM study
Renfrew, A. K., Bryce, N. S., & Hambley, T. W. (2013) · Chemical Science · doi:10.1039/c3sc51530c · Cited by 149
Failes, T. W., Cullinane, C. M., Diakos, C. I., Yamamoto, N., Lyons, J. G., & Hambley, T. W. (2006) · Chemistry - A European Journal · doi:10.1002/chem.200601137 · Cited by 143
Sathyadevi, P., Krishnamoorthy, P., Alagesan, M., Thanigaimani, K., Muthiah, P. T., & Dharmaraj, N. (2011) · Polyhedron · doi:10.1016/j.poly.2011.09.021 · Cited by 108
Inhibition of thermolysin and human α-thrombin by cobalt(III) Schiff base complexes
Takeuchi, T., Böttcher, A., Quezada, C. M., Meade, T. J., & Gray, H. B. (1999) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(98)00272-7 · Cited by 105
17 e − rhenium dicarbonyl CO-releasing molecules on a cobalamin scaffold for biological application
Zobi, F., Blacque, O., Jacobs, R. A., SCHAUB, M. C., & Bogdanova, A. Y. (2011) · Dalton Transactions · doi:10.1039/c1dt10649j · Cited by 102
Dual Targeting of Hypoxic and Acidic Tumor Environments with a Cobalt(III) Chaperone Complex
Yamamoto, N., Renfrew, A. K., Kim, B. J., Bryce, N. S., & Hambley, T. W. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3014713 · Cited by 101
Arsenic compounds as anticancer agents
Wang, Z. (2001) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800100309 · Cited by 89
Kumar, R. S., & Arunachalam, S. (2008) · Biophysical Chemistry · doi:10.1016/j.bpc.2008.05.007 · Cited by 87
Harney, A. S., Lee, J., Manus, L. M., Wang, P., Ballweg, D. M., LaBonne, C., & Meade, T. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906423106 · Cited by 84
Jagadeesan, S., Balasubramanian, V., Baumann, P., Neuburger, M. A., Häußinger, D., & Palivan, C. G. (2013) · Inorganic Chemistry · doi:10.1021/ic4016228 · Cited by 82
Ahn, G., Botting, K. J., Patterson, A. V., Ware, D. C., Tercel, M., & Wilson, W. R. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.03.007 · Cited by 81
Models of hypoxia activated prodrugs: Co(iii) complexes of hydroxamic acids
Failes, T. W., & Hambley, T. W. (2006) · Dalton Transactions · doi:10.1039/b512322d · Cited by 76
Visualising the hypoxia selectivity of cobalt(iii) prodrugs
Kim, B. J., Hambley, T. W., & Bryce, N. S. (2011) · Chemical Science · doi:10.1039/c1sc00337b · Cited by 69
Synthesis and cytotoxicity of a cobaltcarbonyl–alkyne enkephalin bioconjugate
Neukamm, M. A., Pinto, A. V., & Metzler‐Nolte, N. (2007) · Chemical Communications · doi:10.1039/b712886j · Cited by 60
Ruiz-Sánchez, P., König, C., Ferrari, S. M., & Alberto, R. A. (2010) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-010-0697-z · Cited by 59
Cobalt complexes with tripodal ligands: implications for the design of drug chaperones
Bonnitcha, P., Kim, B. J., Hocking, R. K., Clegg, J. K., TURNER, P. R., Neville, S. M., & Hambley, T. W. (2012) · Dalton Transactions · doi:10.1039/c2dt30727h · Cited by 55
Shreaz, S., Sheikh, R. A., Bhatia, R., Neelofar, K., Sheikh, I., Hashmi, A. A., Manzoor, N., Basir, S. F., & Khan, L. A. (2011) · BioMetals · doi:10.1007/s10534-011-9447-0 · Cited by 54
Specific Inhibition of the Transcription Factor Ci by a Cobalt(III) Schiff Base–DNA Conjugate
Hurtado, R. R., Harney, A. S., Heffern, M. C., Holbrook, R. J., Holmgren, R. A., & Meade, T. J. (2012) · Molecular Pharmaceutics · doi:10.1021/mp2005577 · Cited by 54
Ott, I., Koch, T., Shorafa, H., Bai, Z., Poeckel, D., Steinhilber, D., & Gust, R. (2005) · Organic & Biomolecular Chemistry · doi:10.1039/b504294c · Cited by 52
Cellular uptake and distribution of cobalt complexes of fluorescent ligands
Yamamoto, N., Danos, S., Bonnitcha, P., Failes, T. W., New, E. J., & Hambley, T. W. (2008) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-008-0374-7 · Cited by 47
Chang, J. Y.-C., Lu, G., Stevenson, R. J., Brothers, P. J., Clark, G. R., Botting, K. J., Ferry, D. M., Tercel, M., Wilson, W. R., Denny, W. A., et al. (2013) · Inorganic Chemistry · doi:10.1021/ic4006967 · Cited by 46
Milbank, J. B. J., Stevenson, R. J., Ware, D. C., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9008746 · Cited by 43
Ahn, G., Ware, D. C., Denny, W. A., & Wilson, W. R. (2004) · Radiation Research · doi:10.1667/rr3229 · Cited by 42
Anti-tumor effects of nitrosylcobalamin against spontaneous tumors in dogs
Bauer, J. A., Frye, G., Bahr, A. M., Gieg, J. A., & Brofman, P. (2009) · Investigational New Drugs · doi:10.1007/s10637-009-9282-0 · Cited by 19
Cited by
Recent developments in penta-, hexa- and heptadentate Schiff base ligands and their metal complexes
Liu, X., & Hamon, J.-R. (2019) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2019.03.010 · Cited by 390
Metal Drugs and the Anticancer Immune Response
Englinger, B., Pirker, C., Heffeter, P., Terenzi, A., Kowol, C. R., Keppler, B. K., & Berger, W. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00396 · Cited by 355
Radioactive Transition Metals for Imaging and Therapy
Boros, E., & Packard, A. B. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00281 · Cited by 299
Redox‐Active Metal Complexes for Anticancer Therapy
Zhang, P., & Sadler, P. J. (2017) · European Journal of Inorganic Chemistry · doi:10.1002/ejic.201600908 · Cited by 274
Cai, S., Liu, J., Ding, J., Fu, Z., Li, H., Xiong, Y., Lian, Z., Yang, R., & Chen, C. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202204502 · Cited by 255
Metadata
- Authors
- Munteanu, C. R., & Suntharalingam, K.
- Venue
- Dalton Transactions
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2015
- Volume
- 44
- Issue
- 31
- Pages
- 13796-13808
- ISSN
- 1477-9226 (ISSN-L)
- 1477-9234
- OpenAlex
- W1819645169
- Cited by
- 330
- References
- 64
- FWCI
- 6.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.